Abstract
Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a well-established, effective agent for the management of type 2 diabetes mellitus. Epidemiological studies have identified an association between metformin use and a beneficial effect on cancer prevention and treatment, which has led to increasing interest in the potential use of metformin as an anticancer agent. Basic science has provided a better understanding of the mechanism of action of metformin and the potential for metformin to modulate molecular pathways involved in cancer cell signaling and metabolism. This article outlines the link between metformin and cancer, the potential for metformin in oncology, and limitations of currently available evidence.
Original language | English |
---|---|
Pages (from-to) | 17-29 |
Number of pages | 13 |
Journal | Annual Review of Medicine |
Volume | 66 |
Early online date | 6 Nov 2014 |
DOIs | |
Publication status | Published - Jan 2015 |
Keywords / Materials (for Non-textual outputs)
- Diabetes Mellitus, Type 2
- Humans
- Hypoglycemic Agents
- Metformin
- Neoplasms
Fingerprint
Dive into the research topics of 'Metformin in Cancer Treatment and Prevention'. Together they form a unique fingerprint.Profiles
-
Andrew Morris
- Deanery of Molecular, Genetic and Population Health Sciences - Chair of Medicine
- Usher Institute
- Centre for Medical Informatics
Person: Academic: Research Active